,0,1
0,press release,9.0
1,powder inhaler,9.0
2,persuasive evidence,9.0
3,public offering,8.823076923076924
4,bankruptcy protection,8.8
5,balance sheet arrangements,8.7
6,substantial loss,8.682352941176472
7,specialty pharmaceutical,8.631578947368421
8,loan documents,8.53191489361702
9,wa fully amortized,8.487804878048781
10,months,8.444444444444445
11,advance payment,8.375
12,innovative medicine,8.333333333333334
13,health insurance provisions,8.285714285714285
14,existing treatment,8.2
15,adverse effect,8.2
16,months,8.2
17,vendor,8.107287449392713
18,qualitative factor,8.09090909090909
19,agreement,8.066666666666666
20,animal segment information,8.058823529411764
21,tax effect,8.049689440993788
22,temporary difference,8.0
23,corporate purpose,7.978632478632479
24,month,7.963924963924964
25,capital loan,7.934512296214423
26,recurring loss,7.933333333333333
27,administrative employee,7.923128342245989
28,future entry,7.914529914529915
29,additionally sale,7.895522388059701
30,additional funding,7.894910773298083
31,months,7.829787234042553
32,substantial loss,7.815686274509804
33,interest rate,7.800000000000001
34,year beginning,7.793706293706293
35,recent developments,7.777777777777778
36,pharmaceutical product,7.770133164235891
37,pharmaceutical product,7.770133164235891
38,cancer market,7.747368421052632
39,additional dilution,7.742405326674989
40,working capital,7.7359307359307365
41,reporting purpose,7.7272727272727275
42,month,7.71948051948052
43,response letter,7.716666666666667
44,expense,7.710121457489878
45,adamis pharmaceuticals corporation,7.7
46,annual report,7.681632653061224
47,important factor,7.672541743970315
48,pfs product,7.659766338079591
49,future funding,7.633986928104575
50,reporting unit,7.613636363636363
51,loss,7.6
52,offs,7.571428571428571
53,accounting policy,7.542857142857143
54,cancer product candidate,7.53230421686747
55,substantial time,7.525210084033613
56,balance management,7.5166666666666675
57,uncollectible amount,7.490196078431372
58,additional fund,7.48314606741573
59,respiratory market,7.473009446693657
60,explanatory paragraph,7.457142857142857
61,epinephrine pfs,7.418648018648019
62,net loss,7.41159420289855
63,working capital,7.402597402597403
64,sale,7.395522388059701
65,net proceeds,7.394927536231884
66,lived asset,7.385964912280702
67,sufficient funding,7.385448916408668
68,sterile formulation,7.373809523809523
69,year,7.369090909090909
70,class nda resubmissions,7.355555555555556
71,bonus,7.351190476190476
72,month,7.349267753523073
73,exercise price,7.347058823529412
74,product development,7.300716379029632
75,quarterly report,7.281632653061225
76,development,7.269449611554874
77,qualitative factor,7.257575757575758
78,bonus,7.250144592249855
79,subsequently differ materially,7.217391304347826
80,cash resource,7.163636363636364
81,company,7.151785714285714
82,development work,7.145308229577893
83,additional equity,7.129244071045495
84,license agreement,7.129166666666666
85,net proceeds,7.087235228539577
86,financial statement,7.068398268398268
87,financial statement,7.068398268398268
88,financial statement,7.068398268398268
89,clinical trial,7.0574324324324325
90,future cash,7.052525252525253
91,clinical trial,7.009615384615385
92,loan agreement interest,6.998581560283688
93,sum,6.9818181818181815
94,health product,6.964641173389209
95,business stock price,6.951837378307966
96,fiscal wa due,6.939086929330832
97,unexpected development,6.921421421421422
98,agreement interest payment,6.841666666666667
99,usc subsidiary,6.826086956521739
100,provide additional adequate,6.8164794007490634
101,equity financing transaction,6.802848575712144
102,company,6.785119047619048
103,impairment test,6.777777777777777
104,future activity,6.774179037336933
105,response time,6.773809523809524
106,marketing approval,6.7727272727272725
107,step,6.75
108,biotechnology product candidate,6.73230421686747
109,result,6.714251265975404
110,loan amendment agreement,6.7096926713948
111,factor study,6.665909090909091
112,net cash,6.641897233201581
113,amount management,6.640196078431373
114,product candidate,6.629740114303367
115,company,6.618452380952381
116,net cash,6.601897233201582
117,clarification difficulty scheduling,6.571428571428571
118,equity financing sale,6.56793618116315
119,company,6.551785714285714
120,estimate previously disclosed,6.528071411792341
121,condition industry,6.511904761904762
122,united states,6.492753623188406
123,operations information,6.491255961844197
124,directly impact,6.4906976744186045
125,related expense,6.427217660519585
126,stock price term,6.407370975145911
127,merger agreement,6.387987987987988
128,pdufa date,6.366459627329193
129,fasb issued asu,6.342592592592593
130,debt financing sale,6.336698858647937
131,approximately expenses,6.325673950589472
132,additional funding,6.305625059012369
133,sale,6.284411276948591
134,license acquisition,6.281854838709677
135,product,6.26355421686747
136,usc wa completed,6.230558501237186
137,compensation expense,6.195773111535315
138,business combination activity,6.168090681248575
139,production,6.159420289855072
140,event,6.134146341463414
141,company,6.118452380952381
142,actual event,6.005574912891985
143,expense research,5.972527676417837
144,comment,5.966450216450216
145,bank liability,5.963241436925648
146,review recoverability,5.9515789473684215
147,significant investment,5.902615902615903
148,operation satisfy,5.890194235588972
149,wa approximately million,5.880049938687623
150,source,5.764367816091954
151,goodwill impairment review,5.742690058479532
152,asset,5.661605937921728
153,expectation estimate,5.578576462297393
154,statement,5.576190476190476
155,fda approval,5.493723311210577
156,effective april,5.454439446943194
157,working capital,5.402597402597403
158,price,5.331269349845201
159,selling general,5.107287449392713
160,qualitative factor,5.090909090909091
161,recorded monthly based,5.071428571428571
162,compounded formulation,5.016666666666667
163,difficulty scheduling,5.0
164,involves comparing,5.0
165,temporary difference,5.0
166,related factor,4.982213438735178
167,expense,4.969736842105263
168,product,4.926433004746258
169,rate,4.9
170,additional funding,4.894910773298083
171,additional policy,4.88314606741573
172,goodwill,4.803418803418804
173,funding,4.745098039215686
174,previously disclosed,4.737373737373737
175,product candidate,4.73230421686747
176,target deadline,4.714285714285714
177,substantial amount,4.705882352941177
178,annual report,4.681632653061225
179,equity financing,4.672413793103448
180,significant funding,4.671023965141612
181,united states,4.666666666666667
182,unexpected development,4.662162162162162
183,compounded drug,4.648780487804878
184,september adamis,4.644444444444445
185,net cash,4.641897233201581
186,dpi product,4.63855421686747
187,marketing employee,4.636363636363637
188,pharmaceutical biotechnology,4.631578947368421
189,reporting unit,4.613636363636363
190,loan agreement,4.598581560283688
191,compensation expense,4.594736842105263
192,legal expense,4.594736842105263
193,expense,4.582541720154044
194,additional expense,4.577882909520993
195,corporate partner,4.555555555555555
196,prior year,4.551948051948052
197,management,4.55
198,capital resources,4.545454545454545
199,additional information,4.541969596827495
200,expense,4.5271692745376955
201,administrative expense,4.506501547987616
202,delaware corporation,4.5
203,remains hopeful,4.5
204,regulatory work,4.5
205,sufficient fund,4.5
206,individual requirement,4.5
207,adversely affected,4.5
208,qualitative assessment,4.5
209,agreement,4.4990990990991
210,sterile product,4.495697074010327
211,development expenses,4.495495495495495
212,interest expense,4.494736842105263
213,usc,4.492753623188405
214,related expense,4.48604118993135
215,expense,4.48604118993135
216,additional fund,4.48314606741573
217,additional assessment,4.48314606741573
218,net tangible,4.478260869565217
219,net realizable,4.478260869565217
220,financial performance,4.474747474747475
221,transaction,4.463768115942029
222,monthly accrual,4.458333333333334
223,related agreement,4.457971014492754
224,debt financing,4.4411764705882355
225,reserved comment,4.428571428571429
226,month period,4.428571428571429
227,step test,4.416666666666666
228,common stock,4.412486064659978
229,funding,4.411764705882353
230,unpaid interest,4.4
231,june adamis,4.4
232,net proceeds,4.394927536231884
233,bonus travel,4.392857142857142
234,related disclosure,4.391304347826087
235,loan document,4.3890577507598785
236,ha completed,4.383333333333334
237,principal payment,4.375
238,collateral,4.3589743589743595
239,additional consideration,4.35814606741573
240,debt funding,4.352941176470588
241,application,4.344947735191638
242,significantly changed,4.342857142857143
243,future performance,4.333333333333334
244,engaged primarily,4.323529411764706
245,business combination,4.308441558441558
246,product development,4.300716379029632
247,pharmaceutical company,4.283364661654136
248,preferred stock,4.282051282051282
249,quarterly report,4.281632653061225
250,estimated liability,4.263736263736264
251,year,4.255244755244755
252,activity,4.250953470633105
253,satisfactorily addressed,4.25
254,related document,4.248447204968944
255,purchase price,4.247058823529412
256,future business,4.244949494949495
257,planned activity,4.244264507422402
258,interim period,4.242424242424242
259,future achievement,4.222222222222222
260,differ materially,4.217391304347826
261,emergency treatment,4.2
262,intellectual property,4.2
263,revenues adamis,4.2
264,drug product,4.187334704672348
265,contractor,4.181818181818182
266,drug,4.173780487804878
267,applicable law,4.166666666666666
268,cash,4.163636363636364
269,cash resource,4.163636363636364
270,cash,4.163636363636364
271,development pathway,4.162162162162162
272,development effort,4.162162162162162
273,discovery development,4.162162162162162
274,business product,4.161281489594742
275,company,4.1395905923344944
276,product testing,4.13855421686747
277,product validation,4.13855421686747
278,product,4.13855421686747
279,product,4.13855421686747
280,event,4.134146341463414
281,future period,4.1313131313131315
282,similar transaction,4.130434782608695
283,financial condition,4.125541125541126
284,director fee,4.125
285,company,4.118452380952381
286,commercial introduction,4.111111111111111
287,remain open,4.111111111111111
288,goodwill,4.111111111111111
289,goodwill impairment,4.111111111111111
290,effective day,4.111111111111111
291,period adamis,4.109090909090909
292,actual result,4.097701149425287
293,wa approximately,4.088841147478832
294,financial statement,4.068398268398268
295,collaborative agreement,4.066666666666666
296,security agreement,4.066666666666666
297,insurance cost,4.066536203522505
298,recorded net,4.049689440993789
299,drug applications,4.048780487804878
300,drug administration,4.048780487804878
301,drug evaluation,4.048780487804878
302,drug quality,4.048780487804878
303,question,4.0396825396825395
304,future operation,4.038011695906433
305,product sale,4.034076604927171
306,approximately relating,4.033468701862484
307,equipment loan,4.031914893617021
308,march adamis,4.029787234042553
309,materially reduce,4.0269151138716355
310,sterile production,4.023809523809524
311,development activity,4.02181128496918
312,liability,4.015873015873016
313,operation,4.015789473684211
314,potentially reduce,4.0095238095238095
315,net change,4.009510869565217
316,future revenue,4.006006006006006
317,regulatory authority,4.0
318,instance,4.0
319,unmet medical,4.0
320,dose,4.0
321,proposed labeling,4.0
322,steroid hydrofluoroalkane,4.0
323,accumulated deficit,4.0
324,derivative,4.0
325,ultimate success,4.0
326,historical experience,4.0
327,readily apparent,4.0
328,security act,4.0
329,broad range,4.0
330,revenues revenues,4.0
331,remediation effort,4.0
332,independent contractor,4.0
333,device supply,4.0
334,covered person,4.0
335,warf agreements,4.0
336,underwriting discount,4.0
337,continuing development,3.9954954954954953
338,expenditure,3.991304347826087
339,planned expenditure,3.9846153846153847
340,estimate,3.9725158562367864
341,additional research,3.969632553902217
342,significant impact,3.959259259259259
343,merger agreement,3.9555555555555557
344,matter current,3.9545454545454546
345,revenue,3.9504504504504503
346,management plan,3.95
347,guidance,3.9444444444444446
348,development cost,3.9429840799703815
349,manufacture formulation,3.9166666666666665
350,operation,3.9157894736842107
351,comparable period,3.909090909090909
352,drug application,3.9059233449477353
353,sale representative,3.8955223880597014
354,sale discount,3.8955223880597014
355,primarily due,3.890196078431373
356,review process,3.8815789473684212
357,operating activity,3.8596491228070176
358,exchange commission,3.857142857142857
359,future event,3.8563685636856366
360,historical fact,3.833333333333333
361,therapeutic alternative,3.833333333333333
362,mid march,3.829787234042553
363,usc subsidiary,3.8260869565217392
364,primarily focused,3.8235294117647056
365,amount,3.8235294117647056
366,market consideration,3.822368421052632
367,future expenditure,3.8222222222222224
368,company,3.8184523809523805
369,additional submission,3.8164794007490634
370,defer reduce,3.8095238095238093
371,development,3.8079954954954953
372,licensing transaction,3.7971014492753623
373,estimated fair,3.794871794871795
374,growth estimate,3.7906976744186047
375,anticipated commercialization,3.7857142857142856
376,revenue,3.7837837837837838
377,indirect cost,3.780821917808219
378,cost,3.780821917808219
379,item,3.7727272727272725
380,regulatory approval,3.7727272727272725
381,effective date,3.763285024154589
382,condition revenues,3.761904761904762
383,expense,3.76140350877193
384,strategy objective,3.7272727272727275
385,distribution strategy,3.7272727272727275
386,satisfactory data,3.725
387,future research,3.7087087087087087
388,extent statement,3.704761904761905
389,statement,3.704761904761905
390,question,3.7012987012987013
391,judgment,3.6818181818181817
392,life,3.666666666666667
393,definite life,3.666666666666667
394,company,3.6517857142857144
395,company,3.6517857142857144
396,company,3.6517857142857144
397,company,3.6517857142857144
398,continuing operation,3.6491228070175437
399,commercialization activity,3.6453634085213036
400,cost,3.6269757639620654
401,timely manner,3.625
402,adoption,3.625
403,income expense,3.614736842105263
404,business alternative,3.6060606060606064
405,acquired business,3.6060606060606064
406,includes forward,3.6
407,made quarterly,3.5846153846153848
408,derivative liability,3.571428571428571
409,user group,3.571428571428571
410,increase,3.5686274509803924
411,company,3.568452380952381
412,statement,3.5619047619047617
413,data,3.553571428571429
414,bank,3.5473684210526315
415,comparable quarter,3.541666666666667
416,fourth quarter,3.541666666666667
417,private issuance,3.5384615384615383
418,cash,3.5272727272727273
419,accounting contemplates,3.517857142857143
420,circumstance,3.5
421,failure,3.5
422,stockholder,3.5
423,ongoing basis,3.5
424,judgment,3.5
425,similar indication,3.5
426,periodic basis,3.5
427,aggregate deductible,3.5
428,fund research,3.4864864864864864
429,research,3.4864864864864864
430,development,3.4698544698544698
431,operation,3.4616228070175437
432,concern matter,3.4571428571428573
433,company plan,3.4517857142857142
434,amount,3.423529411764706
435,acquisition revenues,3.4193548387096775
436,sales cost,3.405821917808219
437,closing date,3.4021739130434785
438,case,3.392857142857143
439,approximately million,3.3922450606388432
440,contingent asset,3.385964912280702
441,intangible asset,3.385964912280702
442,asset book,3.385964912280702
443,generally made,3.3846153846153846
444,customer,3.3636363636363633
445,obsolete inventory,3.3571428571428568
446,party consultant,3.333333333333333
447,business relationship,3.330419580419581
448,usc subject,3.3260869565217392
449,issue,3.299043062200957
450,treat patient,3.2857142857142856
451,assured revenues,3.2857142857142856
452,asset sale,3.2814873003404035
453,previous filing,3.25
454,larger number,3.25
455,fda determined,3.247311827956989
456,salary increase,3.235294117647059
457,debt obligation,3.235294117647059
458,amount,3.223529411764706
459,present form,3.2222222222222223
460,nda application,3.212698412698413
461,event,3.18970189701897
462,inventory,3.1813186813186816
463,current form,3.176767676767677
464,issue,3.1626794258373208
465,fda apc,3.144747725392887
466,recorded liability,3.142857142857143
467,risk,3.1363636363636367
468,april liquidity,3.117241379310345
469,implied fair,3.1025641025641026
470,company belief,3.0962301587301586
471,valuation allowance,3.0666666666666664
472,sec filing,3.05
473,generic competition,3.0
474,reasonable term,2.9782608695652173
475,approval,2.9602272727272725
476,nda,2.9555555555555557
477,company,2.9375
478,warrant change,2.8512500000000003
479,technology,2.8509615384615383
480,approximately increase,2.8363303870771106
481,responsive submission,2.833333333333333
482,loss,2.8
483,epinephrine,2.7333333333333334
484,section,2.7045454545454546
485,goal,2.6818181818181817
486,factor,2.590909090909091
487,loan,2.5319148936170213
488,month,2.5194805194805197
489,additional,2.4831460674157304
490,customer order,2.474747474747475
491,obtain,2.473684210526316
492,september,2.4444444444444446
493,relating,2.4324324324324325
494,satisfy,2.4285714285714284
495,general,2.423076923076923
496,response,2.4166666666666665
497,funding,2.411764705882353
498,year,2.409090909090909
499,interest,2.4
500,policy,2.4
501,fiscal,2.3846153846153846
502,trial,2.375
503,payment,2.375
504,expected timing,2.3555555555555556
505,provide,2.3333333333333335
506,significant,2.259259259259259
507,clinical,2.25
508,future,2.2222222222222223
509,june,2.2
510,material,2.2
511,human,2.2
512,treatment,2.2
513,disclosed,2.1818181818181817
514,equity,2.1724137931034484
515,include,2.1666666666666665
516,cash,2.1636363636363636
517,development,2.1621621621621623
518,management,2.15
519,bonus,2.142857142857143
520,accounting,2.142857142857143
521,product,2.13855421686747
522,incurred,2.1333333333333333
523,approved,2.125
524,amendment,2.111111111111111
525,effective,2.111111111111111
526,goodwill,2.111111111111111
527,expense,2.094736842105263
528,report,2.0816326530612246
529,agreement,2.066666666666667
530,due,2.066666666666667
531,license,2.0625
532,information,2.0588235294117645
533,business,2.022727272727273
534,biotechnology,2.0
535,adequate,2.0
536,marketing,2.0
537,ultimately,2.0
538,fund,2.0
539,resource,2.0
540,operations,2.0
541,differ,2.0
542,subsidiary,2.0
543,pdufa,2.0
544,provided,2.0
545,indicating,2.0
546,limited,2.0
547,determined,2.0
548,impairment,2.0
549,property,2.0
550,december,1.96
551,current,1.9545454545454546
552,market,1.9473684210526316
553,bank,1.9473684210526316
554,debt,1.9411764705882353
555,question,1.9285714285714286
556,proceeds,1.9166666666666667
557,completed,1.9166666666666667
558,period,1.9090909090909092
559,apc,1.8974358974358974
560,sale,1.8955223880597014
561,affect,1.8888888888888888
562,merger,1.8888888888888888
563,study,1.875
564,activity,1.8596491228070176
565,document,1.8571428571428572
566,application,1.8571428571428572
567,compared,1.8461538461538463
568,expectation,1.8333333333333333
569,continuing,1.8333333333333333
570,patent,1.8333333333333333
571,march,1.8297872340425532
572,usc,1.826086956521739
573,primarily,1.8235294117647058
574,amount,1.8235294117647058
575,operation,1.8157894736842106
576,asu,1.8148148148148149
577,reduce,1.8095238095238095
578,plan,1.8
579,payable,1.8
580,recognition,1.8
581,potential,1.8
582,incur,1.8
583,million,1.7912087912087913
584,estimate,1.7906976744186047
585,commercialization,1.7857142857142858
586,revenue,1.7837837837837838
587,cost,1.7808219178082192
588,issued,1.7777777777777777
589,heading,1.7777777777777777
590,approval,1.7727272727272727
591,raised,1.7727272727272727
592,condition,1.7619047619047619
593,industry,1.75
594,step,1.75
595,strategy,1.7272727272727273
596,obsolete,1.7142857142857142
597,statement,1.7047619047619047
598,impact,1.7
599,source,1.6666666666666667
600,licensing,1.6666666666666667
601,secured,1.6666666666666667
602,improve,1.6666666666666667
603,production,1.6666666666666667
604,allowance,1.6666666666666667
605,obsolescence,1.6666666666666667
606,life,1.6666666666666667
607,date,1.6521739130434783
608,company,1.6517857142857142
609,continue,1.6458333333333333
610,time,1.6428571428571428
611,inventory,1.6428571428571428
612,identified,1.6363636363636365
613,event,1.6341463414634145
614,review,1.631578947368421
615,manner,1.625
616,sales,1.625
617,guidance,1.6111111111111112
618,approximately,1.6010362694300517
619,liquidity,1.6
620,expenditure,1.6
621,resubmitted,1.6
622,agreed,1.6
623,purchase,1.6
624,satisfactory,1.6
625,reported,1.6
626,alternative,1.5833333333333333
627,acquired,1.5833333333333333
628,clarification,1.5714285714285714
629,liability,1.5714285714285714
630,recorded,1.5714285714285714
631,user,1.5714285714285714
632,write,1.5714285714285714
633,reflect,1.5555555555555556
634,quarter,1.5416666666666667
635,issuance,1.5384615384615385
636,intended,1.5384615384615385
637,change,1.53125
638,issue,1.5263157894736843
639,income,1.52
640,april,1.5172413793103448
641,risk,1.5
642,occurring,1.5
643,raise,1.5
644,equipment,1.5
645,responsive,1.5
646,manufacture,1.5
647,stockholder,1.5
648,basis,1.5
649,board,1.5
650,offset,1.5
651,judgment,1.5
652,reasonable,1.5
653,circumstance,1.5
654,aggregate,1.5
655,subject,1.5
656,address,1.5
657,established,1.5
658,credit,1.5
659,competition,1.5
660,indication,1.5
661,generic,1.5
662,research,1.4864864864864864
663,term,1.4782608695652173
664,investment,1.4615384615384615
665,concern,1.457142857142857
666,submit,1.4545454545454546
667,belief,1.4444444444444444
668,normal,1.4444444444444444
669,result,1.4310344827586208
670,submitted,1.4285714285714286
671,realization,1.4285714285714286
672,acquisition,1.4193548387096775
673,required,1.4107142857142858
674,action,1.4
675,adjustment,1.4
676,unsuccessful,1.4
677,valuation,1.4
678,financed,1.4
679,carrying,1.4
680,adopted,1.4
681,registered,1.4
682,excess,1.4
683,determine,1.4
684,asset,1.3859649122807018
685,made,1.3846153846153846
686,based,1.375
687,contemplates,1.375
688,expect,1.375
689,permit,1.375
690,received,1.3636363636363635
691,customer,1.3636363636363635
692,nda,1.3555555555555556
693,submission,1.3333333333333333
694,party,1.3333333333333333
695,note,1.3333333333333333
696,share,1.3333333333333333
697,reserve,1.3333333333333333
698,warrant,1.32
699,technology,1.3125
700,delay,1.3076923076923077
701,relationship,1.3076923076923077
702,ind,1.3
703,obligation,1.2941176470588236
704,requires,1.2857142857142858
705,patient,1.2857142857142858
706,resubmission,1.2857142857142858
707,assured,1.2857142857142858
708,successful,1.2857142857142858
709,entered,1.2857142857142858
710,termination,1.2727272727272727
711,filing,1.25
712,case,1.25
713,section,1.25
714,food,1.25
715,number,1.25
716,commercializing,1.25
717,compounding,1.25
718,meeting,1.25
719,fda,1.2473118279569892
720,increase,1.2352941176470589
721,form,1.2222222222222223
722,lender,1.2222222222222223
723,expected,1.2222222222222223
724,crl,1.2045454545454546
725,request,1.2
726,service,1.2
727,decrease,1.2
728,claim,1.2
729,support,1.1875
730,goal,1.1818181818181819
731,august,1.1666666666666667
732,level,1.1666666666666667
733,contracts,1.1666666666666667
734,notice,1.1666666666666667
735,timing,1.1333333333333333
736,update,1.125
737,order,1.1111111111111112
738,reason,1.1111111111111112
739,fair,1.1025641025641026
740,forward,1.1
741,discussed,1.1
742,good,1.1
743,noted,1.0909090909090908
744,expensed,1.0588235294117647
745,assumption,1.0476190476190477
746,discussion,1.0
747,analysis,1.0
748,results,1.0
749,statements,1.0
750,projection,1.0
751,limitation,1.0
752,word,1.0
753,phrase,1.0
754,guarantee,1.0
755,undertake,1.0
756,filed,1.0
757,securities,1.0
758,uncertainty,1.0
759,communication,1.0
760,addition,1.0
761,commencement,1.0
762,assurance,1.0
763,prevent,1.0
764,occurrence,1.0
765,context,1.0
766,physician,1.0
767,developing,1.0
768,allergy,1.0
769,intend,1.0
770,ndas,1.0
771,abbreviated,1.0
772,andas,1.0
773,save,1.0
774,achieve,1.0
775,center,1.0
776,file,1.0
777,preclude,1.0
778,ability,1.0
779,resolved,1.0
780,agency,1.0
781,receipt,1.0
782,preparing,1.0
783,end,1.0
784,procedure,1.0
785,respond,1.0
786,extended,1.0
787,attempting,1.0
788,commercialized,1.0
789,follow,1.0
790,design,1.0
791,asthma,1.0
792,investigational,1.0
793,commence,1.0
794,outcome,1.0
795,half,1.0
796,pursue,1.0
797,conduct,1.0
798,develop,1.0
799,launch,1.0
800,depleted,1.0
801,obtained,1.0
802,prepared,1.0
803,satisfaction,1.0
804,realizing,1.0
805,recovery,1.0
806,exhaust,1.0
807,unable,1.0
808,attempt,1.0
809,eliminate,1.0
810,visit,1.0
811,depreciation,1.0
812,foregoing,1.0
813,extinguishment,1.0
814,fluctuation,1.0
815,drop,1.0
816,comparison,1.0
817,reduction,1.0
818,inception,1.0
819,total,1.0
820,classified,1.0
821,january,1.0
822,availability,1.0
823,pas,1.0
824,begin,1.0
825,estimates,1.0
826,accordance,1.0
827,preparation,1.0
828,evaluate,1.0
829,base,1.0
830,transfer,1.0
831,assessing,1.0
832,client,1.0
833,considered,1.0
834,connection,1.0
835,acting,1.0
836,extend,1.0
837,delayed,1.0
838,receive,1.0
839,licensee,1.0
840,approve,1.0
841,terminate,1.0
842,borrower,1.0
843,borrow,1.0
844,defined,1.0
845,accrued,1.0
846,sooner,1.0
847,loaned,1.0
848,par,1.0
849,default,1.0
850,october,1.0
851,provision,1.0
852,discus,1.0
853,complexity,1.0
854,operability,1.0
855,understandability,1.0
856,evaluated,1.0
857,pain,1.0
858,men,1.0
859,woman,1.0
860,offered,1.0
861,meet,1.0
862,operates,1.0
863,expand,1.0
864,protocol,1.0
865,reviewed,1.0
866,thing,1.0
867,environment,1.0
868,kind,1.0
869,aspect,1.0
870,part,1.0
871,prepare,1.0
872,suspension,1.0
873,cancellation,1.0
874,relation,1.0
875,criterion,1.0
876,fixed,1.0
877,determinable,1.0
878,collectability,1.0
879,rebate,1.0
880,return,1.0
881,collect,1.0
882,charge,1.0
883,earnings,1.0
884,history,1.0
885,collection,1.0
886,valued,1.0
887,lower,1.0
888,intangibles,1.0
889,identification,1.0
890,indefinite,1.0
891,annually,1.0
892,frequently,1.0
893,totality,1.0
894,deemed,1.0
895,perform,1.0
896,elect,1.0
897,bypass,1.0
898,proceed,1.0
899,likelihood,1.0
900,drive,1.0
901,uncertain,1.0
902,measured,1.0
903,insured,1.0
904,limit,1.0
905,maintain,1.0
906,reversal,1.0
907,demonstrate,1.0
908,reducing,1.0
909,practice,1.0
910,theproduct,1.0
911,thecrl,1.0
912,november,1.0
913,delivery,1.0
914,responsible,1.0
915,surplus,1.0
916,anticipation,1.0
917,resumption,1.0
918,occurred,1.0
919,chemical,1.0
920,expired,1.0
921,certificate,1.0
